D1 and D5 dopamine receptors are coupled to the $G_s$ subtype of G-proteins. Pharmacological inhibition of dopamine receptors D1/D5 in the medial prefrontal cortex (mPFC) causes attention deficit and hyperactivity.
Changes in gene expression are necessary for the appearance of attention deficit and hyperactivity symptoms upon inhibition of D1/D5 receptors. These changes in gene expression are caused by transcription factor cAMP response element binding protein (CREB). Rp-cAMPS is a cell permeable drug that inhibits PKA.
What effects of Rp-cAMPS microinjection into mPFC do you expect to see?